Abstract
Background This study aimed to evaluate the association between the neutrophil to-lymphocyte ratio (NLR) and outcome of septic patients with atrial fibrillation.
Methods Patients with sepsis and AF from the Medical Information Mart for Intensive Care-IV (MIMIC-IV) database had their baseline data and in-hospital prognosis retrieved. Multivariable logistics regression analyses were applied to calculate adjusted odds ratios (OR) with 95% confidence intervals (CI). Survival curves were plotted, and subgroup analyses were stratified by relevant covariates. To address the linearity relationship, curve fitting were performed.
Results Of the 7,241 patients, 5,864 patients with sepsis and AF were included. The overall in-hospital mortality rate was 21.1% (1,235/4,629). Adjusted for confounding factors in the multivariable logistics regression analysis models, when NLR was used as a categorical variable, patients in the highest NLR tertile had increased in-hospital mortality compared to patients in the lowest NLR tertile (HR = 1.31, 95% CI: 1.09–1.58). A linear relationship between NLR and in-hospital mortality was found in patients with sepsis and AF. K-M curves showed the in-hospital mortality rate was highest in group 3(NLRL8.4) than in the other two groups. Stratified analyses indicated that the correlation between the NLR and in-hospital mortality was stable.
Conclusion There is a linear relationship between NLR and in-hospital mortality in intensive care of septic patients with atrial fibrillation. A higher NLR in ICU patients is associated with in-hospital mortality in the United States. However, further research is needed to confirm the findings.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The author(s) received no specific funding for this work.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
MIMIC
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
the URLs/accession numbers/DOIs will be available only after acceptance
